Singapore markets closed

Zentalis Pharmaceuticals, Inc. (ZNTL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.9500-0.3400 (-7.93%)
At close: 04:00PM EDT
3.9500 0.00 (0.00%)
Pre-market: 08:13AM EDT

Zentalis Pharmaceuticals, Inc.

1359 Broadway
Suite 1710
New York, NY 10018
United States
212 433 3791

Full-time employees124

Key executives

NameTitlePayExercisedYear born
Dr. Kimberly Lynn Blackwell M.D.CEO & Director1.17MN/A1969
Mr. Cameron S. Gallagher M.B.A.Co-Founder, President, Interim CFO, Interim Treasurer & Director892.15kN/A1970
Ms. Andrea Paul J.D.Chief Legal Officer & Corporate Secretary682.47kN/A1981
Dr. Diana F. Hausman M.D.Chief Medical Officer & Director38.44kN/A1963
Mr. Vincent VultaggioVP of Finance & Interim Principal Accounting OfficerN/AN/A1983
Dr. Mark Lackner Ph.D.Chief Scientific OfficerN/AN/A1968
Ms. Kimberly FreemanChief Strategy OfficerN/AN/AN/A
Dr. Kyle Rasbach Ph.D., Pharm.D.Chief Business OfficerN/AN/A1980
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Corporate governance

Zentalis Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 July 2024 is 9. The pillar scores are Audit: 7; Board: 6; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.